Cat. #151167
Anti-HPV16E2 [TVG 261]
Cat. #: 151167
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Human Papilloma virus-16 early protein 2 (HPV16 E2)
Class: Monoclonal
Application: IP ; WB ; ELISA ; IF ; WB
Reactivity: Human papilloma virus
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: University of Cambridge
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-HPV16E2 [TVG 261]
- Cancer: Gynaecologic cancer
- Cancers detailed: Cervical
- Research fields: Cancer;Microbiology
- Clone: TVG 261
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 10 kDa
- Strain: Balb/c
- Reactivity: Human papilloma virus
- Host: Mouse
- Application: IP ; WB ; ELISA ; IF ; WB
- Description: TVG 261 is useful for detection of protein in cervical lesions.
- Immunogen: Vaccinia-E2 followed by intravenous injection of the maltose binding protein MBP-E2 (generated from an expression vector in which the E2 ORF was cloned in frame with malE).
- Isotype: IgG1
- Myeloma used: P3/NS1/1-Ag4.1
Target Details
- Target: Human Papilloma virus-16 early protein 2 (HPV16 E2)
- Molecular weight: 10 kDa
- Target background: The human papilloma virus (HPV) family of DNA tumor viruses includes HPV-16 and HPV-18, which are associated with a large proportion of cervical cancer cases. E1 and E2 are proteins involved in the regulation of viral DNA replication.
Applications
- Application: IP ; WB ; ELISA ; IF ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: '-15° C to -25° C
- Shipping conditions: Dry ice
References
- Evans et al. 2019. J Virol. 93(4):. PMID: 30518656.
- Ludwig et al. 2018. Front Oncol. 8:445. PMID: 30370252.
- Evans et al. 2017. Oncotarget. 8(47):81892-81909. PMID: 29137231.
- Campos-Len et al. 2017. J Virol. 91(5):. PMID: 28031358.
- A point mutation within CD45 exon A is the cause of variant CD45RA splicing in humans.
- Hibma et al. 1995. Eur J Biochem. 229(2):517-25. PMID: 7744075.
